Press Releases

Press Releases

Date Title
January 4, 2022
UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022
12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the second half of 2022 Phase 2 study of UBX1325 in wet AMD to include comparison with aflibercept
Displaying 11 - 11 of 11